Avanir Neurodex NDA Delayed By FDA Request For Additional Analyses
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Avanir will meet with FDA "within the next few weeks" to discuss delays in its NDA for Neurodex for treatment of pseudobulbar affect, the firm says